NCT05564858View on ClinicalTrials.gov

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia

FDA022-BB05, intravenously infusion, q3w

DRUG

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib

FDA022-BB05, intravenously infusion, q3w

Trial Locations (1)

100038

RECRUITING

Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Beijing

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY